Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR ...
Acceptance of the drug application by the NMPA marks an essential step in introducing NVK002 as a potential therapeutic option for managing myopia in children across China. “NMPA acceptance of ...
A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review.
Innovent & ASK Pharm Announce NMPA Approval Of Limertinib,3rd-Gen EGFR TKI For Lung Cancer Treatment
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) and Jiangsu Aosaikang Pharmaceutical Co. Ltd. or ASK Pharm announced that China's National Medical Products Administration (NMPA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback